ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity

American Journal of Pathology

Volumn 181, Issue 3, 2012, Pages 1056-1068

  Kumar, Saran ^a   Sharghi Namini, Soheila ^a,b   Rao, Nithya ^a   Ge, Ruowen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 2; PLACENTAL GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; STROMELYSIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; IN VITRO STUDY; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ADAM PROTEINS; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BIOCATALYSIS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; HUMANS; MELANOMA, EXPERIMENTAL; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; SEQUENCE DELETION;

EID: 84865224382     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.05.022     Document Type: Article

References (55)

1. P. Carmeliet Angiogenesis in life, disease and medicine Nature 438 2005 932 936
2. P. Carmeliet Angiogenesis in health and disease Nat Med 9 2003 653 660
3. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 2002 15 18
4. D. Hanahan, R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
5. J. Folkman What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1990 4 6
6. G. Bergers, L.E. Benjamin Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 2003 401 410
7. N. Ferrara, R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974
8. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286
9. V.L. Heath, R. Bicknell Anticancer strategies involving the vasculature Nat Rev Clin Oncol 6 2009 395 404
10. S.S. Apte A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms J Biol Chem 284 2009 31493 31497
11. S. Porter, I.M. Clark, L. Kevorkian, D.R. Edwards The ADAMTS metalloproteinases Biochem J 386 2005 15 27
12. S. Kazerounian, K.O. Yee, J. Lawler Thrombospondins in cancer Cell Mol Life Sci 65 2008 700 712
13. G. Taraboletti, M. Rusnati, L. Ragona, G. Colombo Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors Oncotarget 1 2010 662 673
14. L. Wagstaff, R. Kelwick, J. Decock, D.R. Edwards The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis Front Biosci 16 2011 1861 1872
15. F. Vazquez, G. Hastings, M.A. Ortega, T.F. Lane, S. Oikemus, M. Lombardo, M.L. Iruela-Arispe METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity J Biol Chem 274 1999 23349 23357
16. M. Llamazares, A.J. Obaya, A. Moncada-Pazos, R. Heljasvaara, J. Espada, C. Lopez-Otin, S. Cal The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway J Cell Sci 120 2007 3544 3552
17. A.J. Fosang, F.M. Rogerson, C.J. East, H. Stanton ADAMTS-5: the story so far Eur Cell Mater 15 2008 11 26
18. W. Zeng, C. Corcoran, L.A. Collins-Racie, E.R. Lavallie, E.A. Morris, C.R. Flannery Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18 Biochim Biophys Acta 1760 2006 517 524
19. C. Kintakas, D.R. McCulloch Emerging roles for ADAMTS5 during development and disease Matrix Biol 30 2011 311 317
20. H. Stanton, F.M. Rogerson, C.J. East, S.B. Golub, K.E. Lawlor, C.T. Meeker, C.B. Little, K. Last, P.J. Farmer, I.K. Campbell, A.M. Fourie, A.J. Fosang ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro Nature 434 2005 648 652
21. S.S. Glasson, R. Askew, B. Sheppard, B. Carito, T. Blanchet, H.L. Ma, C.R. Flannery, D. Peluso, K. Kanki, Z. Yang, M.K. Majumdar, E.A. Morris Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis Nature 434 2005 644 648
22. D.R. McCulloch, C.M. Nelson, L.J. Dixon, D.L. Silver, J.D. Wylie, V. Lindner, T. Sasaki, M.A. Cooley, W.S. Argraves, S.S. Apte ADAMTS metalloproteases generate active versican fragments that regulate interdigital web regression Dev Cell 17 2009 687 698
23. D.R. McCulloch, C. Le Goff, S. Bhatt, L.J. Dixon, J.D. Sandy, S.S. Apte Adamts5, the gene encoding a proteoglycan-degrading metalloprotease, is expressed by specific cell lineages during mouse embryonic development and in adult tissues Gene Expr Patterns 9 2009 314 323
24. S. Porter, S.D. Scott, E.M. Sassoon, M.R. Williams, J.L. Jones, A.C. Girling, R.Y. Ball, D.R. Edwards Dysregulated expression of adamalysin- thrombospondin genes in human breast carcinoma Clin Cancer Res 10 2004 2429 2440
25. Y.H. Kim, H.C. Lee, S.Y. Kim, Y.I. Yeom, K.J. Ryu, B.H. Min, D.H. Kim, H.J. Son, P.L. Rhee, J.J. Kim, J.C. Rhee, H.C. Kim, H.K. Chun, W.M. Grady, Y.S. Kim Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations Ann Surg Oncol 18 2011 2338 2347
26. J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, F. Prosper, A. Heiniger, A. Torres Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis J Clin Oncol 23 2005 7043 7049
27. T. Sjoblom, S. Jones, L.D. Wood, D.W. Parsons, J. Lin, T.D. Barber, D. Mandelker, R.J. Leary, J. Ptak, N. Silliman, S. Szabo, P. Buckhaults, C. Farrell, P. Meeh, S.D. Markowitz, J. Willis, D. Dawson, J.K. Willson, A.F. Gazdar, J. Hartigan, L. Wu, C. Liu, G. Parmigiani, B.H. Park, K.E. Bachman, N. Papadopoulos, B. Vogelstein, K.W. Kinzler, V.E. Velculescu The consensus coding sequences of human breast and colorectal cancers Science 314 2006 268 274
28. J. Held-Feindt, E.B. Paredes, U. Blomer, C. Seidenbecher, A.M. Stark, H.M. Mehdorn, R. Mentlein Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas Int J Cancer 118 2006 55 61
29. M. Nakada, H. Miyamori, D. Kita, T. Takahashi, J. Yamashita, H. Sato, R. Miura, Y. Yamaguchi, Y. Okada Human glioblastomas overexpress ADAMTS-5 that degrades brevican Acta Neuropathol 110 2005 239 246
30. S. Sharghi-Namini, H. Fan, K.N. Sulochana, P. Potturi, W. Xiang, Y.S. Chong, Z. Wang, H. Yang, R. Ge The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor Biochem Biophys Res Commun 371 2008 215 219
31. W. Xiang, Z. Ke, Y. Zhang, G.H. Cheng, I.D. Irwan, K.N. Sulochana, P. Potturi, Z. Wang, H. Yang, J. Wang, L. Zhuo, R.M. Kini, R. Ge Isthmin is a novel secreted angiogenesis inhibitor that inhibits tumor growth in mice J Cell Mol Med 15 2011 359 374
32. M.M. Tomayko, C.P. Reynolds Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother Pharmacol 24 1989 148 154
33. N. Ferrara, T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25
34. K.M. Cook, W.D. Figg Angiogenesis inhibitors: current strategies and future prospects CA Cancer J Clin 60 2010 222 243
35. N. Ferrara, H.P. Gerber, J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
36. C. Gendron, M. Kashiwagi, N.H. Lim, J.J. Enghild, I.B. Thogersen, C. Hughes, B. Caterson, H. Nagase Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4 J Biol Chem 282 2007 18294 18306
37. J.M. Longpre, D.R. McCulloch, B.H. Koo, J.P. Alexander, S.S. Apte, R. Leduc Characterization of proADAMTS5 processing by proprotein convertases Int J Biochem Cell Biol 41 2009 1116 1126
38. Y.J. Liu, Y. Xu, Q. Yu Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively Oncogene 25 2005 2452 2467
39. J. Dubail, F. Kesteloot, C. Deroanne, P. Motte, V. Lambert, J.M. Rakic, C. Lapiere, B. Nusgens, A. Colige ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity Cell Mol Life Sci 67 2010 4213 4232
40. P.H. Lo, H.L. Lung, A.K. Cheung, S.S. Apte, K.W. Chan, F.M. Kwong, J.M. Ko, Y. Cheng, S. Law, G. Srivastava, E.R. Zabarovsky, S.W. Tsao, J.C. Tang, E.J. Stanbridge, M.L. Lung Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis Cancer Res 70 2010 5567 5576
41. B.H. Koo, D.M. Coe, L.J. Dixon, R.P. Somerville, C.M. Nelson, L.W. Wang, M.E. Young, D.J. Lindner, S.S. Apte ADAMTS9 is a cell-autonomously acting, anti-angiogenic metalloprotease expressed by microvascular endothelial cells Am J Pathol 176 2010 1494 1504
42. M.D. Tortorella, F. Malfait, R.A. Barve, H.S. Shieh, A.M. Malfait A review of the ADAMTS family, pharmaceutical targets of the future Curr Pharm Des 15 2009 2359 2374
43. J. Lawler The functions of thrombospondin-1 and-2 Curr Opin Cell Biol 12 2000 634 640
44. K. Kuno, K. Bannai, M. Hakozaki, K. Matsushima, K. Hirose The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential Biochem Biophys Res Commun 319 2004 1327 1333
45. A. Luque, D.R. Carpizo, M.L. Iruela-Arispe ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165 J Biol Chem 278 2003 23656 23665
46. C. Ricciardelli, K.M. Frewin, A. Tan Ide, E.D. Williams, K. Opeskin, M.A. Pritchard, W.V. Ingman, D.L. Russell The ADAMTS1 protease gene is required for mammary tumor growth and metastasis Am J Pathol 179 2011 3075 3085
47. D.J. Hicklin, L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1011 1027
48. A. Luttun, M. Tjwa, P. Carmeliet Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders Ann NY Acad Sci 979 2002 80 93
49. S. Liekens, A. Bronckaers, M.J. Perez-Perez, J. Balzarini Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy Biochem Pharmacol 74 2007 1555 1567
50. R. Granata, L. Trovato, E. Lupia, G. Sala, F. Settanni, G. Camussi, R. Ghidoni, E. Ghigo Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms J Thromb Haemost 5 2007 835 845
51. C. Lofqvist, J. Chen, K.M. Connor, A.C. Smith, C.M. Aderman, N. Liu, J.E. Pintar, T. Ludwig, A. Hellstrom, L.E. Smith IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth Proc Natl Acad Sci USA 104 2007 10589 10594
52. R. Granata, L. Trovato, G. Garbarino, M. Taliano, R. Ponti, G. Sala, R. Ghidoni, E. Ghigo Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways FASEB J 18 2004 1456 1458
53. K.R. Molhoek, A.L. Shada, M. Smolkin, S. Chowbina, J. Papin, D.L. Brautigan, C.L. Slingluff Jr. Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R Melanoma Res 21 2011 274 284
54. L. Devy, S. Blacher, C. Grignet-Debrus, K. Bajou, V. Masson, R.D. Gerard, A. Gils, G. Carmeliet, P. Carmeliet, P.J. Declerck, A. Noel, J.M. Foidart The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent FASEB J 16 2002 147 154
55. K. Bajou, C. Maillard, M. Jost, R.H. Lijnen, A. Gils, P. Declerck, P. Carmeliet, J.M. Foidart, A. Noel Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth Oncogene 23 2004 6986 6990